Factory 99% Nilotinib Powder CAS 641571-10-0 Anticancer Chemical Intermediate Nilotinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A705
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Nilotinib
• CAS: 641571-10-0
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Nilotinib
Appearance	White Powder
CAS NO.	641571-10-0
MF	C28H22F3N7O
Storage	Keep in a cool, dry, dark location

 

Nilotinib is an orally administered tyrosine kinase inhibitor (TKI) that targets specific proteins involved in cell signaling. It is designed to block the abnormal activity of these proteins, particularly those associated with certain types of cancer and hematological disorders.

 

1. Cancer Treatment: Nilotinib is primarily prescribed for the treatment of chronic myeloid leukemia (CML), a type of blood cancer characterized by the uncontrolled growth of myeloid cells in the bone marrow.
2. Philadelphia Chromosome-Positive Disorders: It is also used in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), another aggressive form of leukemia.
3. Research and Development: Due to its selective inhibitory properties, nilotinib is also studied in research settings for potential applications in other types of cancers and non-cancerous proliferative disorders.

1. Tyrosine Kinase Inhibition: Nilotinib functions by binding to and inhibiting the activity of the BCR-ABL tyrosine kinase, a fusion protein that results from the Philadelphia chromosome translocation and is responsible for the uncontrolled cell growth in CML and Ph+ ALL.
2. Cell Signaling Modulation: By inhibiting BCR-ABL, nilotinib disrupts the abnormal cell signaling pathways that drive cancer cell proliferation and survival, leading to the reduction of leukemic cell burden.
3. Apoptosis Induction: Additionally, nilotinib has been shown to induce apoptosis (programmed cell death) in leukemic cells, further contributing to its therapeutic effect in treating these hematological malignancies.